
ã³ããæ³šå°ãåäŸã®VAIDSãåŒãèµ·ãããšããæ°ããªç ç©¶çµæ
å èšäºã¯ãã¡ããã/Click here to read the original article.
å é±éææ¥ã«çºè¡šãããç ç©¶ã§ããã¡ã€ã¶ãŒç€Ÿã®ã³ããæ³šå°ãåäŸãã¡ã«VAIDSãåŒãèµ·ããããšã瀺ãããã
ãã®ç ç©¶ã®ç®çã¯ããã¡ã€ã¶ãŒç€Ÿã®ã³ãã "ã¯ã¯ãã³ "ãæ³šå°ãããåäŸãã¡ã®å ç«ã·ã¹ãã ã®æ©èœãžã®åœ±é¿ã調æ»ããããšã§ãã£ãã
ãã®çµæãã³ãããã¯ã¯ãã³ãæ¥çš®ãããåäŸãã¡ã¯ã2åç®ã®æ¥çš®ãã28æ¥åŸãäžè¬çã«ééããããŸããŸãªç åäœã«å¯Ÿããå ç«ç³»ã®åå¿ãäœäžããŠããããšãããã£ããå€ãã®ç¹ç°çãªå ç«åå¿ã¯10å以äžãäœäžããã
ã¯ã¯ãã³æ¥çš®ã«ããç åäœã«å¯Ÿããå ç«ã®äœäžã¯ãã¯ã¯ãã³åŸå€©æ§å ç«äžå šçå矀ïŒVaccine-Acquired Immune Deficiency SyndromeãVAIDSïŒãšåŒã°ãããã®ã§ããã
ãã¡ã€ã¶ãŒç€Ÿã®COVIDã¯ã¯ãã³ãåäŸã®VAIDSãåŒãèµ·ããããšãç ç©¶ã§èšŒæããã
ãããããã³ããã-19ã«å¯Ÿããã¯ã¯ãã³æ¥çš®ããç°çš®ç åäœã«å¯Ÿããå ç«ã®èããäœäžãåŒãèµ·ããããšãç§åŠçã«ç¢ºèªãããã ç°çš®ç åäœãšã¯ãä»ã®ãŠã€ã«ã¹ã现èãçèãªã©ãç°ãªãçç©ã«ç±æ¥ããããšããæå³ã§ããããã®ä»ã®ç åäœã«å¯Ÿããå ç«åã®äœäžãã€ãŸãåŸå€©æ§å ç«äžå šãã人ã ã¯ä¿ã« "VAIDS "ãšåŒãã§ãããVAIDSãšã¯ã¯ã¯ãã³åŸå€©æ§å ç«äžå šçå矀ã®ç¥ã§ããã
BNT162b2 COVID-19ã¯ã¯ãã³æ¥çš®ãç°çš®ç åäœããã³Tollæ§å容äœã¢ãŽãã¹ãã«å¯Ÿãããµã€ãã«ã€ã³å¿çãå€åãããããšé¡ããããã®ç ç©¶ã§ã¯ããã¡ã€ã¶ãŒç€Ÿã®ã³ãã "ã¯ã¯ãã³ "ãæ³šå°ãããåäŸãã¡ã®å ç«å¿çã®è³ªã枬å®ããããšããã
5æ³ãã11æ³ã®å°å 29人ã®è¡æ¶²ãµã³ãã«ããã³ããã¯ã¯ãã³ã®1åç®ã®æ¥çš®æ¥ã«æ¡åããããã®åŸ2åç®ã®æ¥çš®åŸ28æ¥ç®ã«åæ¡åãããã
æ¹æ³ ç°çš®åºæ¿ç©ïŒæ»æ» ç åäœãTollæ§å容äœãªã¬ã³ãïŒããã³SARS-CoV-2æåã«å¯Ÿããin vitroãµã€ãã«ã€ã³å¿çã調ã¹ãããã«å šè¡åºæ¿ã¢ãã»ã€ãçšããã5ïœ11æ³ã®å°å 29äººã®æ€äœãã2åç®ã®BNT162b2ã¯ã¯ãã³æ¥çš®åãšæ¥çš®28æ¥åŸã«åæããïŒV2ïŒ28ïŒãBNT162b2ã¯ã¯ãã³æ¥çš®6ãµæåŸã«8人ã®å°å ã®æ€äœãåæããã
åé ã§ç§åŠè ãã¡ã¯ãã¯ã¯ãã³æ¥çš®ãããµã€ãã«ã€ã³åå¿ãå€åãããããšãã©ããããµã€ãã«ã€ã³ãšã¯ãç§ãã¡ã®å ç«ã·ã¹ãã ãææã«åå¿ããŠç£çããå°ããªã¿ã³ãã¯è³ªã®ããšã§ããã ãããã倿ããããã«ãäºé²æ¥çš®ã¯å ç«åå¿ãæ¹åããã©ããããæªåãããã®ã§ããïŒ
çµè« å°å ã«ãããBNT162b2ã¯ã¯ãã³æ¥çš®ã¯ãç¹ã«ã¯ã¯ãã³æ¥çš®1ãµæåŸã«ç°çš®åºæ¿ç©ã«å¯Ÿãããµã€ãã«ã€ã³å¿çãå€åããããæ¬ç ç©¶ã¯ãå°å ã«ãããCOVID-19ã¯ã¯ãã³æ¥çš®ã®å ç«åŠçç°çš®äœçšãåããŠå ±åãããã®ã§ããã
ç§åŠè ãã¡ã¯äœãããã
ãµã³ãã«åé
åå è ã¯ã2åã®ã³ã¢èšªåãš1åã®ãªãã·ã§ãã«èšªåã§è¡æ¶²ãµã³ãã«ã®æäŸãæ±ããããã1åç®ã®è¡æ¶²ãµã³ãã«ã¯ã1åç®ã®BNT162b2ã¯ã¯ãã³æ¥çš®ã®çŽåããã³åæ¥ã«æ¡åãïŒV1ïŒã2åç®ã®è¡æ¶²ãµã³ãã«ã¯ã2åç®ã®BNT162b2ã¯ã¯ãã³æ¥çš®ã®28æ¥åŸã«æ¡åãïŒV2ïŒ28ïŒãä»»æã®3åç®ã®è¡æ¶²ãµã³ãã«ã¯ã2åç®ã®BNT162b2ã¯ã¯ãã³æ¥çš®ã®6ã«æåŸã«æ¡åããïŒV2ïŒ182ïŒïŒè£è¶³å³S1ïŒãæå€§23mLã®éèè¡ããããªã³ãããªãŠã 嫿ã»è¡æž åé¢ãã¥ãŒãïŒBecton Dickinson, NJ, USAïŒã«æ¡åããã
ãã®åŸãæ¡åããè¡æ¶²ã§ãäžè¬çã«ééããããŸããŸãªçްèãé»è²ãããŠçèãç åæ§é µæ¯ã«ã³ãžãã»ã¢ã«ãã«ã³ã¹ãªã©ãããŸããŸãªç åäœã«å¯Ÿããå ç«åå¿ãæ€æ»ããïŒ
詊éšç®¡å ïŒin vitroïŒå šè¡åºæ¿æ³
in vitroå šè¡åºæ¿ã¢ãã»ã€ã¯ã以åã«èšèŒãããããã«è¡ããã(16, 23)ã[å®éšå®€äœæ¥ã®è©³çްã¯çç¥-I.C.ã...ä»ã®åºæ¿ç©ã¯ä»¥åã«èšèŒãããŠãã(16)ã以äžãå«ãïŒçްèåºæ¿ç©(ç±æ®ºHaemophilus influenzae type BãHK Listeria monocytogenesãBCG-DenmarkãHK Staphylococcus aureusããã³HK Escherichia coli)ãããã³ãŠã€ã«ã¹ïŒä»ã®åºæ¿ç©(BåèçãŠã€ã«ã¹è¡šé¢æåã...ãHK Candida albicansã
äžèšã®å€ãã¯ãç§ãã¡ãé »ç¹ã«ééããç åäœã§ãããç§ãã¡ãç¥ããäžããããå ç«ã·ã¹ãã ãæã£ãŠããã®ã¯ãããããé ãããããã§ãããå¥åº·ãªåäŸãã¡ã¯éåžžããããŠããã
æ®å¿µãªããã5æ³ãã11æ³ã®ã³ããã»ã¯ã¯ãã³æ¥çš®ãåãã29人ã®åäŸãã¡ã¯ããã¡ã€ã¶ãŒã®2åç®ã®æ¥çš®ãã28æ¥åŸãå ç«åå¿ãèããäœäžããŠãããå€ãã®ç¹ç°çãªå ç«åå¿ã¯10å以äžãäœäžããã
ç ç©¶ã®èè ã¯ããè¿°ã¹ãŠããïŒ
ç°çš®çްèãçèããã³ãŠã€ã«ã¹/TLRã¢ãŽãã¹ãåºæ¿åŸãV1ãšV2 + 28ã®éã§ãå°å ã®ãµã€ãã«ã€ã³ããã³ã±ã¢ã«ã€ã³å¿çã¯å šè¬çã«æžå°ãããæå€§ã®æžå°ã¯IFN-γãšMCP-1ã«ã¿ãããïŒå³2ã3A-CïŒãIL-6ãIL-15ãIL-17ããŸããBCGãH. influenzaeãS. aureusãBåèçæåãpoly(I: C)ãR848ã§åºæ¿ããåŸãV1ãšV2 + 28ã®éã§æžå°ããïŒå³3BïŒãL. monocytogenesåºæ¿ã«ãããIL-15ãTNF-αãIP-10ã¯V1ãšV2 + 28ã®éã§æžå°ããïŒå³3CïŒãIL-8å¿çããŸããH. influenzaeããã³S. aureusåºæ¿åŸãV1ãšV2 + 28ã®éã§æžå°ããã
é»è²ãããŠçèã«å¯Ÿããåå¿ã®äœäžã¯éåžžã«æ·±å»ã§ããããã®ç æ°ã¯æ²»çãé£ãããèšãç¥ããªã害ããããããèªè ãããŸãåæºãããªãããã«ãææªã®åçã¯çç¥ããã

ãããã«ãããå ç«åå¿ã®äœäžã¯å šäœçã«èµ·ããã
çæ³çãªäžçã§ã¯ãæ³šææ·±ãç§åŠè ãæ éãªå ¬è¡è¡çåœå±ããããŠä¿¡å¿µã®ããå»åž«ãã¡ããäœåäžäººãã®åã©ããã¡ãäœåå人ãã®å€§äººã«ã¯ã¯ãã³ãæ¥çš®ããåã«ãã³ããæ³šå°ã®åœ±é¿ã調æ»ããã¯ãã§ããããã圌ãããã³ãããã¯ã¯ãã³ãã®æ¥çš®ã矩åä»ããæ³šå°ããåã«ãäžèšã®ç ç©¶ã®ãããªåºç€ç§åŠã調æ»ããå®è¡ããŠããã°ããã®ãããªå±éºãªæ³šå°ãåã©ããè¥è ã«æãããããšã¯ãªãã£ãã ããïŒ
ãã®ä»£ããã«ãå¹ããããªããã¯ã¯ãã³ãããäžçäžã«æ¥çš®ãããããšèºèµ·ã«ãªã£ãçµæãäœçŸäžäººãã®åã©ããã¡ããããŠããããä»ã®äººãã¡ã®å ç«åå¿ãå°ç¡ãã«ããŠããŸã£ãã®ã ã
äžèšã®çްèã«ææããåã©ããã¡ããåå äžæã®å¢å ããããŠãããšããèŠåºããããµããŠããïŒ

æ éã«æ€èšããã©ããããç§åŠãšä¿å¥åœå±ã¯ãã¹ãŠãåŠå®ããè°è«ãæåŠãããçå®ãæããã«ãªãã€ã€ããä»ãã³ããæ³šå°ã®æªåœ±é¿ã¯ãã¯ãèŠããªããéåžžã«æ®å¿µãªããšã ïŒ